Journal of Hepatology
Volume 49, Issue 3 , Pages 329-338 , September 2008

Prospective analysis of effector and regulatory CD4+ T cells in chronic HCV patients undergoing combination antiviral therapy

  • James R. Burton Jr.

      Affiliations

    • University of Colorado Denver, School of Medicine, Division Gastroenterology & Hepatology, Hepatitis C Research Center, Aurora, CO, USA
    • ,
  • Jared Klarquist

      Affiliations

    • University of Colorado Denver, School of Medicine, Division Gastroenterology & Hepatology, Hepatitis C Research Center, Aurora, CO, USA
    • ,
  • KyungAh Im

      Affiliations

    • University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, USA
    • ,
  • Sue Smyk-Pearson

      Affiliations

    • University of Colorado Denver, School of Medicine, Division Gastroenterology & Hepatology, Hepatitis C Research Center, Aurora, CO, USA
    • ,
  • Lucy Golden-Mason

      Affiliations

    • University of Colorado Denver, School of Medicine, Division Gastroenterology & Hepatology, Hepatitis C Research Center, Aurora, CO, USA
    • ,
  • Nicole Castelblanco

      Affiliations

    • University of Colorado Denver, School of Medicine, Division Gastroenterology & Hepatology, Hepatitis C Research Center, Aurora, CO, USA
    • ,
  • Norah Terrault

      Affiliations

    • University of California – San Francisco, Division of Gastroenterology and Hepatology, San Francisco, CA, USA
    • ,
  • Hugo R. Rosen

      Affiliations

    • University of Colorado Denver, School of Medicine, Division Gastroenterology & Hepatology, Hepatitis C Research Center, Aurora, CO, USA
    • Corresponding Author InformationCorresponding author. Present address: Waterman Professor of Medicine and Immunology, Division Head, Gastroenterology & Hepatology, GI & Hepatology Division, B-158 Academic Office Building 1, 12631 East 17th Avenue, Room 7614, P.O. Box 6511, Aurora, CO 80045, USA. Tel.: +1 303 724 1858; fax: +1 303 724 1891.
    • ,
  • for the Virahep-C Study Group

Received 28 December 2007 ,Revised 22 April 2008 ,Accepted 7 May 2008.

References 

  1. Dienstag JL, McHutchison JG. American gastroenterological association technical review on the management of hepatitis C. Gastroenterology. 2006;130:231–264
  2. Davis GL, Albright JE, Cook SE, Rosenberg D. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl. 2003;9:331–338
  3. Hadziyannis SJ, Sette HJ, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346–355
  4. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med. 2001;194:1395–1406
  5. Lechner F, Wong DK, Dunbar PR, Chapman R, Chung RT, Dohrenwend P, et al. Analysis of successful immune responses in person infected with hepatitis C virus. J Exp Med. 2000;191:1499–1512
  6. Tang KH, Herrmann E, Cooksley H, Tatman N, Chokshi S, Williams R, et al. Relationship between early HCV kinetics and T-cell reactivity in chronic hepatitis C genotype 1 during peginterferon and ribavirin. J Hepatol. 2005;43:776–782
  7. Barnes E, Salio M, Cerundolo V, Medlin J, Murphy S, Dusheiko G, et al. Impact of alpha interferon and ribavirin on the function of maturing dendritic cells. Antimicrob Agents Chemother. 2004;48:3382–3389
  8. Luft T, Pang KC, Thomas E, Hertzog P, Hart DN, Trapani J, et al. Type I IFNs enhance the terminal differentiation of dendritic cells. J Immunol. 1998;161:1947–1953
  9. Li K, Foy E, Ferreon JC, Nakamura M, Ferreon ACM, Ikeda M, et al. Immune evasion of hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor adaptor protein TRIF. Proc Natl Acad Sci USA. 2005;102:2992–2997
  10. Foy E, Li K, Wang C, Sumpter R, Ikeda M, Lemon SM, et al. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science. 2003;300:1145–1148
  11. Taylor DR, Shi ST, Romano PR, Barber GN, Lai MM. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science. 1999;285:107–110
  12. Grotta S, Stilla A, Wack A, D’Andrea A, Nuti S, D’Oro U, et al. Inhibition of natural killer cells through the engagement of CD81 by the major hepatitis C virus envelope protein. J Exp Med. 2002;195:35–42
  13. Kamal SM, Fehr J, Roesler B, Peters T, Rasenack JW. Peginterferon alone or with ribarivin enhances HCV-specific CD4+ T-helper 1 responses in patients with chronic hepatitis C. Gastroenterology. 2002;123:1070–1083
  14. Cramp ME, Rossol S, Chokshi S, Carucci P, Williams R, Naoumov NV. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology. 2000;118:346–355
  15. Barnes E, Harcourt G, Brown D, Lucas M, Phillips R, Dusheiko G, et al. The dynamics of T-lymphocyte responses during combination therapy for chronic hepatitis C virus infection. Hepatology. 2002;36:743–754
  16. Kaplan DE, Sugimoto K, Ikeda F, Stadanlick J, Valiga M, Shetty K, et al. T-cell response relative to genotype and ethnicity during antiviral therapy for chronic hepatitis C. Hepatology. 2005;41:1365–1375
  17. Pilli M, Zerbini A, Penna A, Orlandini A, Lukasiewicz E, Pawlotsky JM, et al. HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV Project). Gastroenterology. 2007;133:1132–1143
  18. Yamano Y, Takenouchi N, Li H-C, Tomaru U, Yao K, Grant CW, et al. Virus-induced dysfunction of CD4+CD25+ T cells in patients with HTLV-I-associated neuroimmunological disease. J Clin Invest. 2005;115:1361–1368
  19. Cabrera R, Tu Z, Xu Y, Firpi RJ, Rosen HR, Liu C, et al. An immunomodulatory role for CD4(+)CD25(+) regulatory T lymphocytes in hepatitis C virus infection. Hepatology. 2003;40:1062–1071
  20. Sugimoto K, Ikeda F, Stadanlick J, Nunes NA, Alter HJ, Chang KM. Suppression of HCV-specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infection. Hepatology. 2003;38:1437–1448
  21. Boettler T, Spangenberg HC, Neumann-Haefelin C, Panther E, Urbani S, Ferrari C, et al. T cells with a CD4+CD25+ regulatory phenotype suppress in vitro proliferation of virus-specific CD8+ T cells during chronic hepatitis C virus infection. J Virol. 2005;79:7860–7867
  22. Conjeevaram HS, Fried MW, Jeffers LJ, Terrault NA, Wiley-Lucas TE, Afhal N, et al. Peginterferon and ribavirin treatment in African Americans and Caucasian American patients with hepatitis C genotype 1. Gastroenterology. 2006;131:470
  23. Rosen HR, Weston SJ, Im K, Yang H, Burton JR, Erlich H, et al. Selective decrease in hepatitis C virus-specific immunity among African Americans and outcome of antiviral therapy. Hepatology. 2007;46:350–358
  24. Rushbrook SM, Ward SM, Unitt E, Vowler SL, Lucas M, Klenerman P, et al. Regulatory T cells suppress in vitro proliferation of virus-specific CD8+ T cells during persistent hepatitis C virus infection. J Virol. 2005;79:7852–7859
  25. Mills KH. Regulatory T cells: friend or foe in immunity to infection?. Nat Rev Immunol. 2004;4:841–855
  26. Schwartz RH. Natural regulatory T cells and self-tolerance. Nat Rev Immunol. 2005;6:327–330
  27. Zheng SG, Wang JH, Stohl W, Kim KS, Gray JD, Horwitz DA. TGF-beta requires CTLA-4 early after T cell activation to induce FoxP3 and generate adaptive CD4+CD25+ regulatory cells. J Immunol. 2006;176:3321–3329
  28. Oderup C, Cederbom L, Makowska A, Cilio CM, Ivars F. Cytotoxic T lymphocyte antigen-4-dependent down-modulation of costimulatory molecules on dendritic cells in CD4+CD25+ regulatory T-cell-mediated suppression. Immunology. 2006;118:240–249
  29. Macon-Lemaitre L, Triebel F. The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells. Immunology. 2005;115:170–178
  30. Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med. 2004;199:971–979
  31. Younes SA, Trautmann L, Yassine-Diab B, Kalfayan LH, Kernaleguen AE, Cameron TO, et al. The duration of exposure to HIV modulates the breadth and the magnitude of HIV-specific memory CD4+ T cells. J Immunol. 2007;178:788–797
  32. Semmo N, Day CL, Ward SM, Lucas M, Harcourt G, Loughry A, et al. Preferential loss of IL-2-secreting CD4+ T helper cells in chronic HCV infection. Hepatology. 2005;41:1019–1028
  33. Rehermann B, Naoumov NV. Immunological techniques in viral hepatitis. J Hepatol. 2007;46:508–520
  34. Aberle JH, Perstinger G, Weseslindtner L, Sinzinger U, Gurguta C, Steindl-Munda P, et al. CD4+ T cell responses in patients with chronic hepatitis C undergoing peginterferon/ribavirin therapy correlate with faster, but not sustained, viral clearance. J Infect Dis. 2007;195:1315–1319
  35. Rahman F, Heller T, Sobao Y, Mizukoshi E, Nascimbeni M, Alter H, et al. Effects of antiviral therapy on the cellular immune response in acute hepatitis C. Hepatology. 2004;40:87–97

☆ Dr. Terrault receives honoraria and grant support from Roche Pharmaceuticals. No other authors have a potential conflict of interest to report . NIH funded study . This study was funded as a cooperative agreement by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) with co-support from the National Center on Minority Health and Health Disparities (NCMHD) and the Intramural Research Program of the National Cancer Institute (NCI) with further support under a Cooperative Research and Development Agreement (CRADA) with Roche Laboratories, Inc. Grant Nos: U01 DK60329, U01 DK60340, U01 DK 60324, U01 DK 60344, U01 DK60327, U01 DK 60335, U01 DK60352, U01DK 60342, U01 DK 60345, U01 DK 60309, U01 DK 60346, U01 DK 60349, U01 DK 60341. Other support: National Center for Research Resources (NCRR) General Clinical Research Centers Program Grants: M01 RR00645 (New York Presbyterian), M02 RR000079 (University of California, San Francisco), M01 RR 16500 (University of Maryland), M01 RR000042 (University of Michigan), M01 RR00046 (University of North Carolina).

PII: S0168-8278(08)00370-X

doi: 10.1016/j.jhep.2008.05.020

Journal of Hepatology
Volume 49, Issue 3 , Pages 329-338 , September 2008

Article Tools

* Image Usage & Resolution